Lundbeck

When two leading Australian generic drug manufacturers challenged the patent for the antidepressant, Lexapro, the landmark Australian case raised questions about the novelty and inventive step of enantiomers (mirror forms of a molecule), exclusive use of regulatory data and patent term extensions.

Corrs’ representation of the patent owner, Lundbeck, required close collaboration with the in-house counsel of the Danish research company, US and British lawyers to co-ordinate strategy and the use of expert witnesses in more than one jurisdiction to secure the only case in which the novelty and inventive step in isolating a single enantiomer has been upheld by Australian Courts.